Saturday 17 October 2026 Export PRAX’s income statement to Excel — free account

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023. In the quarter to June 2026, revenue grew 1,349.1%, EPS grew 13.3% and free cash flow fell 43.5%, each against the same quarter a year earlier.

241.76 6.48 −2.61%

Follow PRAX

Alert me

Market cap: $6.9B
P/E: 0.0×
Fwd P/E: −24.3×
Dividend yield: —
F-score: n/a
Altman Z: 19.09
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 11.08

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	—	—	—	—	—	—	1	—	—	—	—

Insider Ownership 9.86%

Capital & Financial Ratios $m

Market Cap 6,930.00

Revenue 8.55

Net Income (339.13)

Free Cash Flow (306.16)

Net Debt (758.55)

Current Ratio 15.73

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (24.30)

P/S ratio 823.42

P/B ratio 5.25

Past 5Y EPS Growth —

This Y EPS Growth (1.74%)

Next Y EPS Growth 26.89%

Next Y revenue growth (97.21%)

Next 5Y EPS Growth 16.47%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/B against its own 10 years 82.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	81	393	599	759
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	85	404	611	772

	2023	2024	2025	Q'26
Payables	6	13	25	23
ST’ Debt	—	—	—	—
Other	—	—	—	—
	16	38	60	49

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	25.03%	125.97%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	0	0	7	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(86)	(78)	—	—	—
’25	(53)	(55)	(65)	(76)	(249)
’24	(21)	(27)	(27)	(56)	(132)
’23	(33)	(31)	(23)	(24)	(111)
’22	(54)	(57)	(45)	(29)	(185)
’21	(26)	(30)	(24)	(45)	(125)
’20	(9)	(10)	(14)	(20)	(53)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(86)	(79)	—	—	—
’25	(53)	(55)	(65)	(76)	(249)
’24	(21)	(27)	(27)	(56)	(132)
’23	(33)	(31)	(23)	(24)	(111)
’22	(54)	(57)	(45)	(29)	(185)
’21	(26)	(30)	(24)	(45)	(126)
’20	(9)	(10)	(14)	(20)	(53)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.20)	(2.87)	—	—	—
’25	(3.29)	(3.31)	(3.36)	(3.50)	(13.48)
’24	(2.84)	(1.74)	(2.75)	(2.94)	(10.21)
’23	(10.64)	(7.35)	(2.70)	(2.97)	(18.69)
’22	(22.64)	(19.79)	(14.39)	(13.04)	(69.56)
’21	(10.64)	(13.19)	(14.99)	(19.49)	(59.07)
’20	(76.67)	(105.62)	(181.41)	(13.04)	(117.84)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	358.50	190.65	22.20	11.85	20.50	26.70	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	877.35	914.27	309.00	78.75	86.93	317.72
People
People	Employees	—	—	—	37	67	139	109	82	116	168
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.03	0.07	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	2	9	—
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	100.00	100.00	—
	EBT	—	—	(26)	(36)	(62)	(167)	(214)	(123)	(183)	(303)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	(5,037.88)	(2,137.48)	0.00
	Net income	—	0	(27)	(36)	(62)	(167)	(214)	(123)	(183)	(303)
	Depreciation	—	—	0	0	0	2	1	0	(5)	(3)
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.37	0.48	0.00
	Earnings	—	—	(306.49)	(347.98)	(117.84)	(59.07)	(69.56)	(18.69)	(10.21)	(13.48)
	Cash flow	—	—	(239.27)	(327.33)	(88.15)	(43.99)	(60.22)	(16.85)	(7.36)	(11.07)
	Capex	—	—	(0.73)	(1.01)	0.00	(0.37)	(0.14)	(0.01)	0.00	0.00
	Free cash flow	—	—	(240.00)	(328.33)	(88.15)	(44.36)	(60.36)	(16.86)	(7.36)	(11.07)
	Book value	—	—	(473.88)	(793.42)	481.50	88.57	24.77	10.57	24.88	39.02
	Shares, m	—	—	0	0	1	3	3	7	18	23
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	0.00	0.00	—
	P/S	—	—	—	—	—	—	—	56.32	161.13	—
	P/B	—	—	—	—	—	—	—	1.98	3.09	—
	EV/Sales	—	—	—	—	—	—	—	23.10	115.23	—
	EV/FCF	—	—	—	—	—	—	—	(0.51)	(7.47)	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(21)	(33)	(53)	(125)	(185)	(111)	(132)	(249)
	Capex	—	—	0	0	—	(1)	0	0	—	0
	Free cash flow	—	—	(21)	(34)	(53)	(126)	(185)	(111)	(132)	(249)
Balance, $m
Balance, $m	Working capital	—	—	14	39	287	249	76	69	367	551
	Total debt	—	—	—	1	1	4	4	—	—	—
	Net debt	—	—	(18)	(45)	(297)	(276)	(100)	(81)	(393)	(599)
	Shareholders’ equity	—	—	(41)	(81)	287	251	76	70	445	878
Returns, %
Returns, %	ROA	—	—	(294.75)	(120.50)	(40.08)	(56.07)	(104.95)	(121.41)	(64.03)	(42.68)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(236.57)	(73.12)
	ROE	—	—	47.89	66.67	(68.13)	(62.07)	(130.94)	(169.13)	(70.98)	(45.83)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)	Compare
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
SYRE Spyre Therapeutics, Inc.	$7.4B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−50.07% (below 0%: shrinking)	0.00%	0.00%	Compare
IONS Ionis Pharmaceuticals, Inc.	$7.3B	— (loss-making)	— (loss-making)	−40.73% (below 0%: shrinking)	n/m	+299.29% (above 0%: growing)	98.98%	(38.18%)	Compare
PRAX Praxis Precision Medicines, Inc.	$6.9B	— (loss-making)	— (loss-making)	+1,349.13% (above 0%: growing)	n/m	−43.54% (below 0%: shrinking)	100.00%	0.00%
IOVA Iovance Biotherapeutics, Inc.	$6.7B	— (loss-making)	— (loss-making)	+65.65% (above 0%: growing)	n/m	+11.52% (above 0%: growing)	56.10%	(52.26%)	Compare
BLTE Belite Bio, Inc. Sponsored ADR	$6.2B	— (loss-making)	—	—	n/m	+64.67% (above 0%: growing)	—	0.00%	Compare
RYTM Rhythm Pharmaceuticals, Inc.	$6.1B	— (loss-making)	— (loss-making)	+46.91% (above 0%: growing)	n/m	+60.74% (above 0%: growing)	87.47%	(68.14%)	Compare
LGND Ligand Pharmaceuticals Incorporated	$6.0B	29.5×	54.7×	+33.73% (above 0%: growing)	+868.00% (above 0%: growing)	+35.53% (above 0%: growing)	94.95%	13.49%	Compare
Median of peers	$7.0B	—	—	+40.32%	—	+23.53%	87.47%	(19.09%)

All 614 Biotechnology stocks →

Praxis Precision Medicines, Inc. (PRAX) key facts

Strength: Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
Praxis Precision Medicines, Inc. (PRAX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PRAX traded at $241.76, a market capitalization of $6.9 billion.
Return on equity was −45.8% and debt-to-equity 0.00.
Its Altman Z-score is 19.09 (safe zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.